Optimal dosage and differences in therapeutic efficacy of IGIV in Kawasaki disease.
In an initial study, three groups of patients with Kawasaki disease received either aspirin alone or alkylated immunoglobulin G intravenous preparation (IGIV) 200 mg/kg daily x 3 days + aspirin, or 400 mg/kg alkylated IGIV daily x 3 days + aspirin. In a second study, three groups of patients were treated with either 100, 200 or 400 mg/kg of native IGIV in combination with aspirin daily for 5 days. While the regimen of 200 mg/kg native IGIV daily x 5 days was found to be effective, the incidence of coronary artery lesions (CAL) was even less on a regimen of 400 mg/kg daily x 5 days. It is therefore suggested that a better therapeutic effect can be achieved with a 400 mg/kg dose of native IGIV. Based on the results from these two studies, it is assumed that native IGIV is more effective in inhibiting CAL formation and persistence than the chemically modified preparation in which the biological activity of the Fc region in the immunoglobulin G molecule is altered.
Onouchi
Z
Z
Division of Pediatrics, Children's Research Hospital, Kyoto Prefectural University of Medicine, Japan.
Yanagisawa
M
M
Hirayama
T
T
Kiyosawa
N
N
Matsuda
H
H
Nakashima
M
M
D001241:Aspirin / Q000008:administration & dosage; D016009:Chi-Square Distribution; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000628:therapy*
D016756:Immunoglobulins, Intravenous; D001241:Aspirin